Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Nov 06  •  04:00PM ET
3.98
Dollar change
+0.11
Percentage change
2.84
%
Index- P/E16.81 EPS (ttm)0.24 Insider Own21.59% Shs Outstand56.89M Perf Week4.19%
Market Cap226.60M Forward P/E- EPS next Y-0.76 Insider Trans0.00% Shs Float44.64M Perf Month-0.25%
Enterprise Value104.52M PEG2.10 EPS next Q-0.18 Inst Own58.42% Short Float13.88% Perf Quarter65.83%
Income14.44M P/S3.24 EPS this Y131.37% Inst Trans-3.23% Short Ratio6.76 Perf Half Y135.50%
Sales70.00M P/B1.71 EPS next Y-291.88% ROA9.13% Short Interest6.20M Perf YTD85.98%
Book/sh2.33 P/C1.59 EPS next 5Y7.99% ROE11.85% 52W High4.45 -10.56% Perf Year33.11%
Cash/sh2.51 P/FCF- EPS past 3/5Y28.55% -5.22% ROIC9.65% 52W Low1.20 233.05% Perf 3Y69.36%
Dividend Est.- EV/EBITDA20.70 Sales past 3/5Y- - Gross Margin99.51% Volatility6.86% 7.00% Perf 5Y-87.37%
Dividend TTM- EV/Sales1.49 EPS Y/Y TTM116.50% Oper. Margin6.72% ATR (14)0.25 Perf 10Y-
Dividend Ex-Date- Quick Ratio8.73 Sales Y/Y TTM- Profit Margin20.63% RSI (14)55.16 Recom1.12
Dividend Gr. 3/5Y- - Current Ratio8.73 EPS Q/Q48.50% SMA201.53% Beta3.33 Target Price9.00
Payout- Debt/Eq0.16 Sales Q/Q- SMA5011.09% Rel Volume1.05 Prev Close3.87
Employees24 LT Debt/Eq0.13 EarningsNov 06 BMO SMA20056.11% Avg Volume916.36K Price3.98
IPOJan 30, 2020 Option/ShortYes / Yes EPS/Sales Surpr.35.98% - Trades Volume963,732 Change2.84%
Date Action Analyst Rating Change Price Target Change
Oct-16-25Resumed Stifel Buy $8
Sep-04-25Initiated Guggenheim Buy $8
Jul-01-25Resumed Raymond James Outperform $11
Jul-31-24Initiated Raymond James Outperform $20
Jul-14-23Initiated Piper Sandler Overweight
Jun-30-23Upgrade Stifel Hold → Buy $2 → $10
Jun-28-23Upgrade H.C. Wainwright Neutral → Buy $11
Jun-27-23Upgrade Wedbush Neutral → Outperform $10
Mar-29-22Downgrade Wedbush Outperform → Neutral
Mar-22-22Downgrade H.C. Wainwright Buy → Neutral
Today 04:01PM
07:37AM
07:30AM
Oct-31-25 02:00PM
Oct-22-25 09:24AM
09:20AM Loading…
Oct-15-25 09:20AM
Oct-09-25 09:52AM
09:40AM
Oct-07-25 09:15AM
Sep-25-25 12:53PM
Sep-23-25 10:23AM
Sep-22-25 09:40AM
Sep-16-25 09:47AM
Sep-12-25 09:08AM
Sep-05-25 10:53AM
10:46AM Loading…
Sep-04-25 10:46AM
Aug-19-25 12:00PM
Aug-18-25 09:40AM
Aug-07-25 07:47AM
07:30AM
Jul-15-25 04:58PM
May-29-25 08:00AM
May-12-25 04:05PM
Apr-26-25 11:00AM
Mar-31-25 08:00AM
Mar-25-25 12:58AM
Mar-20-25 10:42AM
Mar-19-25 07:00AM
Mar-06-25 04:09PM
04:01PM
09:15AM Loading…
Feb-19-25 09:15AM
Jan-12-25 06:05AM
Nov-05-24 09:00AM
08:00AM
Nov-01-24 08:00AM
Oct-07-24 04:01PM
Sep-23-24 11:43AM
07:00AM
Sep-22-24 10:00AM
Sep-14-24 03:30AM
Aug-08-24 04:05PM
12:00PM
Aug-06-24 01:53PM
07:37AM
07:30AM
Jun-29-24 08:28PM
06:30PM
Jun-01-24 10:00AM
May-29-24 08:00AM
May-16-24 08:23AM
May-10-24 08:46AM
May-09-24 01:54PM
07:30AM
07:28AM
Apr-29-24 08:50AM
Apr-25-24 09:55AM
Apr-24-24 04:05PM
Apr-23-24 07:45AM
Apr-15-24 12:00PM
Apr-11-24 08:00AM
Apr-08-24 09:55AM
Apr-07-24 06:00PM
Apr-03-24 08:00AM
Mar-22-24 09:55AM
Mar-14-24 05:31AM
Mar-12-24 08:32AM
08:00AM
Mar-05-24 04:30PM
Feb-28-24 08:00AM
Jan-04-24 08:00AM
Dec-13-23 07:00AM
Nov-07-23 08:00AM
Nov-06-23 08:07AM
07:48AM
07:45AM
Oct-20-23 12:54PM
Oct-14-23 12:30PM
Oct-04-23 12:14PM
Sep-18-23 12:34PM
07:00AM
Sep-11-23 08:00AM
Sep-05-23 08:00AM
Aug-17-23 09:56AM
Aug-11-23 07:35AM
07:30AM
Jul-25-23 07:43AM
Jul-16-23 10:05AM
Jun-29-23 08:57PM
05:48PM
Jun-28-23 04:23PM
07:15AM
Jun-27-23 07:00AM
Jun-13-23 08:00AM
Jun-02-23 08:00AM
May-18-23 10:17AM
May-09-23 07:46AM
07:30AM
Apr-18-23 08:00AM
Apr-17-23 04:01PM
Mar-09-23 07:52AM
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The company's MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type-mediated toxicities, and be brain-penetrant to treat central nervous system diseases. It is currently focused on advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. The company was founded by David M. Epstein and Elizabeth Buck in 2014 and is headquartered in Cambridge, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BIOTECH GROWTH N V10% OwnerMar 19 '25Sale2.075,784,29211,997,7492,733,547Mar 20 09:01 PM